Welcome to our dedicated page for Neurosense Therapeutics news (Ticker: NRSN), a resource for investors and traders seeking the latest updates and insights on Neurosense Therapeutics stock.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical-stage biotechnology company developing novel treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. Its news flow centers on the clinical and regulatory progress of its lead drug candidate, PrimeC, a novel extended-release oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, in a fixed dose designed to target multiple disease mechanisms.
News updates for NRSN commonly cover milestones in ALS and Alzheimer’s clinical programs. These include Phase 2 and Phase 2b trial readouts, such as the PARADIGM study in ALS and the RoAD proof-of-concept study in Alzheimer’s disease, along with biomarker analyses that the company uses to interpret treatment effects. Press releases also highlight safety and tolerability findings, including reports of favorable safety profiles and absence of new or unexpected safety signals in clinical studies.
Investors and observers can expect coverage of regulatory interactions, such as FDA clearance to initiate a pivotal Phase 3 trial of PrimeC in ALS, database lock announcements for Alzheimer’s trials, and updates on planned submissions to agencies like Health Canada. Corporate and financing developments, including private placements of ordinary shares and business updates, are also frequent topics.
This news page aggregates these company-issued announcements, SEC-related communications and other public disclosures about NeuroSense’s progress. It is useful for readers who want to follow NRSN’s clinical trial milestones, biomarker-driven research updates, regulatory steps and capital-raising activities as the company advances PrimeC in ALS and Alzheimer’s disease.
NeuroSense (Nasdaq: NRSN) reported 2025 results and a business update. PrimeC advanced to a late-stage asset with FDA clearance to start the Phase 3 PARAGON trial and Phase 2b PARADIGM showed ~33% slowing of progression over 18 months.
In early 2026 the company reported a 65% reduction in risk of death and a >14-month median survival benefit; results were published in JAMA Neurology. Financials show $0.2M cash at Dec 31, 2025 and a $11.125M net loss for 2025. Key near-term milestones include a May 2026 pre-NDS meeting in Canada and Alzheimer’s readouts.
NeuroSense (NASDAQ:NRSN) updated regulatory and clinical progress for lead asset PrimeC. A Health Canada pre‑NDS meeting was rescheduled to May 2026 to include additional clinical, biomarker and survival data intended to strengthen the submission.
The company expects an Alzheimer's study clinical and biomarker readout in the coming weeks and cites a previously disclosed 65% reduction in risk of death and FDA clearance to start the pivotal Phase 3 PARAGON ALS trial.
NeuroSense (NASDAQ: NRSN) announced that Dr. Christian Lunetta will present new clinical and biomarker data on PrimeC for ALS at AD/PD 2026 in Copenhagen on March 19, 2026. The presentation reviews Phase 2b PARADIGM findings and biomarker analyses that informed the design of the planned global Phase 3 PARAGON trial.
PARADIGM data were recently published in JAMA Neurology, and NeuroSense says it is actively engaging regulators as PARAGON — a multinational, randomized, double-blind, placebo-controlled study — is advanced to further evaluate PrimeC's safety and efficacy.
NeuroSense (NASDAQ: NRSN) announced that Dr. Christian Lunetta will present new clinical and biomarker data on PrimeC for ALS at AD/PD™ 2026 on March 19, 2026 in Copenhagen.
The presentation reviews Phase 2b PARADIGM findings, cites publication in JAMA Neurology, and outlines plans for the multinational Phase 3 PARAGON trial while the company maintains regulatory engagement.
NeuroSense (NASDAQ: NRSN) announced JAMA Neurology publication of PARADIGM Phase 2b results for PrimeC in ALS, reporting slower functional decline, reduced complications, and biomarker activity.
Key findings: 7.92-point ALSFRS-R advantage at 18 months (~36% slowing, p=0.007), 64% relative reduction in ALS complications (p=0.02), favorable safety vs placebo, and modulation of iron and microRNA biomarkers.
NeuroSense (NASDAQ: NRSN) will present long-term survival data from the Phase 2b PARADIGM trial of PrimeC at the MDA Clinical & Scientific Conference on March 9, 2026. The analysis showed a 65% reduction in risk of death (HR 0.35; p=0.0037) and a >14-month median survival benefit (36.3 vs. 21.4 months; log-rank p=0.0218).
The randomized, double-blind, placebo-controlled study enrolled 68 participants (2:1 randomization) with a six-month double-blind period followed by an open-label extension; safety was described as favorable.
NeuroSense (NASDAQ: NRSN) reported extended PARADIGM Phase 2b survival data showing a median survival of 36.3 months with continuous PrimeC versus 21.4 months for initial placebo, an improvement of over 14 months (~70% increase).
Adjusted analysis showed a 65% reduction in risk of death (HR 0.35; 95% CI 0.17–0.71; p=0.0037) and a statistically significant log-rank p=0.0218. The randomized 68-patient trial included a 2:1 active:placebo double-blind period and an open-label extension; company engagement with regulators continues.
NeuroSense (Nasdaq: NRSN) announced that IP Australia granted Australian Patent No. 2022370513 for compositions comprising ciprofloxacin and celecoxib, extending patent protection for PrimeC through October 2042.
The grant follows a corresponding U.S. patent (12,097,185) and strengthens the company’s global exclusivity strategy as PrimeC advances toward pivotal Phase 3 development in ALS after positive Phase 2b PARADIGM results and FDA clearance of the Phase 3 protocol.
NeuroSense (NASDAQ: NRSN) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,527,768 for a PrimeC combination therapy for Alzheimer's disease, extending patent protection through 2043. The patent covers compositions combining an anti-inflammatory drug and a Dicer activator for neuronal diseases, which the company says strengthens its intellectual property for long-term development and potential commercialization.
NeuroSense also completed a proof-of-concept Alzheimer's study (RoAD) with top-line results showing a favorable safety and tolerability profile. Clinical and biomarker outcomes from the study are expected in Q1 2026.
NeuroSense (NASDAQ: NRSN) announced that Prof. Steven E. Arnold, a noted Alzheimer's expert and Professor of Neurology at Harvard Medical School, has joined its Scientific Advisory Board.
The company said Prof. Arnold brings biomarker-driven clinical development and translational neuroscience experience as NeuroSense advances its PrimeC programs in ALS and Alzheimer's disease. NeuroSense reported that its proof-of-concept Alzheimer's study (RoAD) showed a favorable safety and tolerability profile, and that clinical and biomarker outcomes from RoAD are expected in Q1 2026.